Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Radiation Oncology
•
Thoracic Malignancies
Is there a role for radiation to the primary mediastinal disease in metastatic thymic neuroendocrine carcinoma with the primary as the only residual disease after systemic therapy?
What dose would you use to treat?
Related Questions
Given the results of LU002 presented at ASCO 2024, are there situations and/or patient subgroups who still derive benefit from local consolidative therapy for oligometastatic NSCLC?
Is moderately hypofractionated RT using 60 Gy/20fx with concurrent chemotherapy appropriate for unresectable stage III NSCLC?
Do you have different hotspot and heterogeneity goals for SBRT of ground glass lesions vs more solid adenocarcinoma NSCLC lesions?
How do you assess whether a patient will be a good DIBH candidate for lung or abdomen treatments?
What is the role of consolidative durvalumab and prophylactic cranial irradiation in patients with stage I small cell lung cancer?
Would you offer lung SBRT in a patient with Pulmonary Langerhans Cell Histiocytosis (PLCH)?
What dose contraints do use for the pulmonary artery and vein when treating with a lung lesion with SBRT?
Do you restrict the dose rate during treatment delivery to a pacemaker in addition to limiting the Dmax?
Is there increased risk with lung SBRT in a patient who has a mild asymptomatic pneumothorax in the field after CT-guided needle biopsy?
How would you approach an in-field recurrence after lung SBRT for a T1 NSCLC in a patient with poor underlying lung function?